2,6-二氯-5-氟代烟酰氯 | 96568-02-4

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2,6-二氯-5-氟代烟酰氯
• 中文别名: 2,6-二氯-5-氟烟酰氯
• 英文名称: 2,6-dichloro-5-fluoro-3-nicotinoyl chloride
• 英文别名: 2,6-dichloro-5-fluoronicotinoyl chloride；2,6-dichloro-5-fluoropyridine-3-carbonyl chloride；2,6-dichloro-5-fluoro-3-pyridinecarbonyl chloride；2,6-dichloro-5-fluoronicotinyl chloride；2,6-dichloro-5-fluoropyridine-3-formyl chloride；2,6-dichloro-5-fluoro-pyridine-3-carboxylic acid chloride
• CAS: 96568-02-4
• 化学式: C₆HCl₃FNO
• mdl: MFCD01863240
• 分子量: 228.437
• InChiKey: AATVXELAYCLVTJ-UHFFFAOYSA-N

物化性质

• 沸点：
  238-239 °C(lit.)
• 密度：
  1.640 g/mL at 25 °C(lit.)
• 闪点：
  >230 °F
• pKa：
  -6.00±0.10 (Predicted,Most Basic Temp: 25 °C)
• 稳定性/保质期：

  遵照规定使用和储存，则不会发生分解。

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  30
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C
• 危险类别码：
  R34
• 危险品运输编号：
  UN 3265 8/PG 2
• WGK Germany：
  3
• 海关编码：
  2933399090
• 安全说明：
  S26,S36/37/39,S45
• 储存条件：
  存放于阴凉干燥处

SDS

Name:	2 6-Dichloro-5-Fluoronicotinoyl Chloride 90% Material Safety Data Sheet
Synonym:	None Known
CAS:	96568-02-4

Section 1 - Chemical Product MSDS Name:2 6-Dichloro-5-Fluoronicotinoyl Chloride 90% Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
96568-02-4	2,6-Dichloro-5-Fluoronicotinoyl Chlori	90%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Vapors may be heavier than air. They can spread along the ground and collect in low or confined areas. Runoff from fire control or dilution water may cause pollution.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam. Do NOT get water inside containers.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation. Do not get water inside containers.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Do not allow contact with water. Wash clothing before reuse. Keep from contact with moist air and steam.
Storage:
Store in a tightly closed container. Store in a dry area. Keep refrigerated. (Store below 4C/39F.) Store protected from moisture.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 96568-02-4: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Clear liquid
Color: yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C6HCl3FNO
Molecular Weight: 228.3705

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, moisture, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents, moisture.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 96568-02-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,6-Dichloro-5-Fluoronicotinoyl Chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 96568-02-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 96568-02-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 96568-02-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

化学性质：液体。

用途：作为萘啶类抗微生物药物的中间体。

生产方法：通过将2,6-二羟基烟酸酯在锂试剂作用下与三氯氧磷反应进行氯化，随后氟化处理，并使用溶剂稀释、过滤和蒸馏得到该产品。

反应信息

• 作为反应物：
  描述：

  2,6-二氯-5-氟代烟酰氯 以 乙醇 为溶剂， 反应 1.25h， 以95%的产率得到2,6-二氯-5-氟吡啶-3-羧酸乙酯
  参考文献：
  名称：

  New Pyridine Analogues IX 519

  摘要：

  本发明涉及某些新的Formula (I)的吡啶类似物，涉及制备这类化合物的方法，它们作为P2Y12抑制剂和抗血栓药物等的用途，它们在心血管疾病中作为药物的使用，以及含有它们的药物组合物。

  公开号：

  US20080171732A1
• 作为产物：
  描述：

  2,6-二氯-5-氟吡啶-3-羧酸乙酯 在 盐酸 、 氯化亚砜 、 三氟乙酸 作用下， 以 水 为溶剂， 反应 28.5h， 生成 2,6-二氯-5-氟代烟酰氯
  参考文献：
  名称：

  ANTIVIRAL AND ANTIMICROBIAL COMPOUNDS

  摘要：

  本文披露了具有抗病毒和抗菌活性的胍和双胍衍生物。还披露了含有这些化合物作为活性成分的药物组合物，以及利用这些化合物的抗病毒和抗菌方法。还披露了使用胍和双胍衍生物治疗感染的方法。

  公开号：

  US20140073631A1

文献信息

• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2015180612A1

  公开（公告）日：2015-12-03

  Disclosed are novel retinoid-related orphan receptor gamma (RORγ) modulators and their use in the treatment of diseases mediated by RORγ.

  揭示了新型视黄醇相关孤儿受体γ（RORγ）调节剂及其在通过RORγ介导的疾病治疗中的应用。
• Rational design, synthesis and testing of novel tricyclic topoisomerase inhibitors for the treatment of bacterial infections part 1
  作者：R. Kirk、A. Ratcliffe、G. Noonan、M. Uosis-Martin、D. Lyth、O. Bardell-Cox、J. Massam、P. Schofield、S. Hindley、D. R. Jones、J. Maclean、A. Smith、V. Savage、S. Mohmed、C. Charrier、A-M. Salisbury、E. Moyo、R. Metzger、N. Chalam-Judge、J. Cheung、N. R. Stokes、S. Best、M. Craighead、R. Armer、A. Huxley

  DOI：10.1039/d0md00174k

  日期：——

  and topoisomerase IV inhibitors that demonstrate potent activity against a range of Gram-positive and selected Gram-negative organisms, including clinically-relevant and drug-resistant strains. In part 1, we present a detailed structure activity relationship (SAR) analysis that led to the discovery of our previously disclosed compound, REDX05931, which has a minimum inhibitory concentration (MIC) of

  针对细菌感染的药物有效性令人震惊的下降，迫切需要开发新的抗菌剂来绕过细菌耐药机制。我们在此报告了一系列 DNA 促旋酶和拓扑异构酶 IV 抑制剂，它们对一系列革兰氏阳性和选定的革兰氏阴性生物体（包括临床相关和耐药菌株）表现出有效的活性。在第 1 部分中，我们提出了详细的构效关系 (SAR) 分析，导致我们发现了我们之前公开的化合物 REDX05931，该化合物对耐氟喹诺酮类金黄色葡萄球菌的最小抑制浓度 (MIC) 为 0.06 μg mL -1。虽然在体外 hERG 和 CYP 抑制阻止了进一步的发展，它验证了一种合理的设计方法来解决这一紧迫的未满足的医疗需求，并为进一步优化提供了一个支架，在第 2 部分中介绍。
• Development of novel 2-substituted acylaminoethylsulfonamide derivatives as fungicides against Botrytis cinerea
  作者：Minlong Wang、Ying Du、Chunhui Liu、Xinling Yang、Peiwen Qin、Zhiqiu Qi、Mingshan Ji、Xinghai Li

  DOI：10.1016/j.bioorg.2019.03.017

  日期：2019.6

  2-ethoxyacetylamide derivative (V-A-12, EC50 = 0.66 mg·L−1) exhibited the highest potency in vitro and superior fungicidal activity compared with procymidone (EC50 = 1.06 mg·L−1). In vivo bioassay indicated that compound V-A-12 could be effective for the control of tomato gray mold. Moreover, the structure-activity relationship of these sulfonamides was analyzed by establishing a three-dimensional quantitative structure-activity

  灰葡萄孢是经济上重要的真菌病原体，其宿主范围超过200种植物。不幸的是，由于灰质芽孢杆菌引起的灰霉病由于其产生抗真菌剂的高风险而没有得到有效控制。我们一直在努力发展新的磺酰胺作为对抗农业杀真菌剂的一部分灰霉病，我们介绍了2-氨基乙磺酸（牛磺酸）子结构，设计并合成了一系列新的2-取代的acylaminoethylsulfonamides的。对新合成的磺酰胺类药物在体外和体内对灰葡萄孢的杀真菌活性进行了评估，其中2-乙氧基乙酰酰胺衍生物（VA-12，EC 50  = 0.66 mg·L -1）在体外表现出最高的效价，并且与丙咪唑 酮（EC 50 = 1.06 mg·L -1）相比具有更好的杀真菌活性。体内生物测定表明，化合物VA-12可有效控制番茄灰霉病。此外，通过建立三维定量构效关系（3D-QSAR）模型，对这些磺酰胺的构效关系进行了分析，可为磺酰胺类杀菌剂的开发提供指导。最后，在抗灰葡萄孢
• 1,6-naphthyridine derivatives and their use to treat diabetes and related disorders
  申请人：——

  公开号：US06677352B1

  公开（公告）日：2004-01-13

  The invention relates generally to naphthyridine derivatives of the formula wherein one of U, X, Y and Z is nitrogen and the others are C—R, where R is hydrogen or a substituent. More specifically, the invention relates to 1,6-naphthyridine derivatives and pharmaceutical compositions containing such derivatives. Methods of the invention comprise administration of a naphthyridine derivative of the invention for the treatment of diabetes and related disorders.

  本发明一般涉及萘啶衍生物，其公式为： ``` ... ``` 其中U、X、Y和Z中有一个是氮，其余是C-R，其中R是氢或取代基。更具体地说，本发明涉及1,6-萘啶衍生物和包含此类衍生物的药物组合物。本发明的方法包括用于治疗糖尿病和相关障碍的萘啶衍生物的给药。
• [EN] DIHYDROOROTATE DEHYDROGENASE INHIBITORS<br/>[FR] INHIBITEURS DE DIHYDROOROTATE DÉSHYDROGÉNASE
  申请人：JANSSEN BIOTECH INC

  公开号：WO2020144638A1

  公开（公告）日：2020-07-16

  Disclosed are compounds, compositions and methods for treating diseases, disorders, or medical conditions that are affected by the modulation of DHODH. Such compounds are represented by Formula (I) as follows: wherein R1a, R1b, R2, and R3, are defined herein.

  揭示了一种通过调节DHODH来治疗受影响的疾病、疾病或医疗状况的化合物、组合物和方法。这些化合物由以下式（I）表示：其中R1a、R1b、R2和R3在此处定义。